Latest Insider Transactions at National Healthcare Corp (NHC)
This section provides a real-time view of insider transactions for National Healthcare Corp (NHC). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of NATIONAL HEALTHCARE CORP to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of NATIONAL HEALTHCARE CORP's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 21
2023
|
Ben Anderson Sr Flatt Senior VP & CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,296
-27.13%
|
$253,792
$77.33 P/Share
|
|
Nov 21
2023
|
Ben Anderson Sr Flatt Senior VP & CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,733
+23.5%
|
$235,179
$63.96 P/Share
|
|
Nov 21
2023
|
Brian F Kidd SVP, CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,296
-13.8%
|
$253,792
$77.33 P/Share
|
|
Nov 21
2023
|
Brian F Kidd SVP, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,733
+13.52%
|
$235,179
$63.96 P/Share
|
|
Nov 21
2023
|
Robert Michael Ussery President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,501
-2.27%
|
$269,577
$77.33 P/Share
|
|
Nov 21
2023
|
Robert Michael Ussery President & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,233
+2.68%
|
$266,679
$63.96 P/Share
|
|
Nov 21
2023
|
Josh A Mc Creary Senior VP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
3,296
-46.96%
|
$253,792
$77.33 P/Share
|
|
Nov 21
2023
|
Josh A Mc Creary Senior VP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
3,733
+34.72%
|
$235,179
$63.96 P/Share
|
|
Nov 21
2023
|
Leroy E. Mc Intosh Jr. SVP, Anc Srvcs & Srvc Strategy |
SELL
Payment of exercise price or tax liability
|
Direct |
3,296
-31.51%
|
$253,792
$77.33 P/Share
|
|
Nov 21
2023
|
Leroy E. Mc Intosh Jr. SVP, Anc Srvcs & Srvc Strategy |
BUY
Exercise of conversion of derivative security
|
Direct |
3,733
+26.3%
|
$235,179
$63.96 P/Share
|
|
Nov 21
2023
|
Stephen Fowler Flatt CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,261
-6.99%
|
$328,097
$77.33 P/Share
|
|
Nov 21
2023
|
Stephen Fowler Flatt CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,733
+7.21%
|
$298,179
$63.96 P/Share
|
|
Nov 16
2023
|
Stephen Fowler Flatt CEO |
SELL
Bona fide gift
|
Direct |
800
-1.4%
|
-
|
|
Sep 29
2023
|
Emil E Hassan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+2.42%
|
$128,000
$64.64 P/Share
|
|
Sep 06
2023
|
Robert G Adams Director |
BUY
Open market or private purchase
|
Indirect |
2,000
+39.73%
|
$130,000
$65.4 P/Share
|
|
Aug 24
2023
|
James Paul Abernathy Director |
SELL
Open market or private sale
|
Direct |
1,550
-4.94%
|
$105,400
$68.22 P/Share
|
|
Aug 11
2023
|
Sandra Y. Trail Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,807
+33.33%
|
$124,683
$69.19 P/Share
|
|
Aug 09
2023
|
W Andrew Adams Director |
BUY
Open market or private purchase
|
Direct |
1,861
+4.16%
|
$124,687
$67.17 P/Share
|
|
Jun 29
2023
|
Richard F Laroche Jr Director |
BUY
Open market or private purchase
|
Direct |
2,100
+1.06%
|
$128,100
$61.4 P/Share
|
|
May 15
2023
|
Ernest G Burgess Iii Director |
BUY
Open market or private purchase
|
Indirect |
2,300
+2.7%
|
$133,400
$58.85 P/Share
|
|
Mar 08
2023
|
Leroy E. Mc Intosh Jr. SVP, Anc Srvcs & Srvc Strategy |
BUY
Grant, award, or other acquisition
|
Direct |
619
+8.43%
|
-
|
|
Mar 08
2023
|
Robert Michael Ussery President & COO |
BUY
Grant, award, or other acquisition
|
Direct |
1,332
+0.88%
|
-
|
|
Mar 08
2023
|
Jeffrey Russell Smith SVP & Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
418
+4.96%
|
-
|
|
Mar 08
2023
|
Stephen Fowler Flatt CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,502
+2.57%
|
-
|
|
Mar 08
2023
|
Josh A Mc Creary Senior VP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
728
+18.14%
|
-
|
|
Mar 08
2023
|
Vicki L Dodson Sr.VP Patient Srvcs |
BUY
Grant, award, or other acquisition
|
Direct |
573
+14.11%
|
-
|
|
Mar 08
2023
|
Brian F Kidd SVP, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
728
+3.49%
|
-
|
|
Mar 08
2023
|
Ben Anderson Sr Flatt Senior VP & CIO |
BUY
Grant, award, or other acquisition
|
Direct |
697
+7.65%
|
-
|
|
Feb 23
2023
|
James Paul Abernathy Director |
BUY
Open market or private purchase
|
Direct |
2,176
+6.48%
|
$124,032
$57.45 P/Share
|
|
Jan 01
2023
|
Jeffrey Russell Smith SVP & Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
362
-4.55%
|
$21,358
$59.5 P/Share
|
|
Jan 01
2023
|
Josh A Mc Creary Senior VP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
297
-10.41%
|
$17,523
$59.5 P/Share
|
|
Jan 01
2023
|
Brian F Kidd SVP, CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
318
-1.61%
|
$18,762
$59.5 P/Share
|
|
Jan 01
2023
|
Vicki L Dodson Sr.VP Patient Srvcs |
SELL
Payment of exercise price or tax liability
|
Direct |
194
-6.24%
|
$11,446
$59.5 P/Share
|
|
Jan 01
2023
|
Stephen Fowler Flatt CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
824
-1.46%
|
$48,616
$59.5 P/Share
|
|
Jan 01
2023
|
Ben Anderson Sr Flatt Senior VP & CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
362
-4.67%
|
$21,358
$59.5 P/Share
|
|
Dec 15
2022
|
W Andrew Adams Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,020
+4.7%
|
$123,220
$61.9 P/Share
|
|
Dec 13
2022
|
Sandra Y. Trail Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,807
+50.0%
|
$124,683
$69.19 P/Share
|
|
Dec 06
2022
|
Ernest G Burgess Iii Director |
SELL
Open market or private sale
|
Direct |
531
-0.65%
|
$30,798
$58.9 P/Share
|
|
Dec 05
2022
|
Ernest G Burgess Iii Director |
SELL
Open market or private sale
|
Direct |
1,929
-2.32%
|
$117,669
$61.15 P/Share
|
|
Dec 02
2022
|
Ernest G Burgess Iii Director |
SELL
Open market or private sale
|
Direct |
7,652
-4.31%
|
$466,772
$61.06 P/Share
|
|
Dec 01
2022
|
Ernest G Burgess Iii Director |
SELL
Open market or private sale
|
Direct |
888
-0.49%
|
$53,280
$60.68 P/Share
|
|
Nov 30
2022
|
Ernest G Burgess Iii Director |
SELL
Open market or private sale
|
Direct |
2,444
-1.31%
|
$146,640
$60.92 P/Share
|
|
Aug 10
2022
|
Ernest G Burgess Iii Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+2.59%
|
$152,500
$61.9 P/Share
|
|
May 18
2022
|
Robert G Adams Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
1,934
+0.45%
|
$123,776
$64.64 P/Share
|
|
May 11
2022
|
James Paul Abernathy Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,020
+6.47%
|
$123,220
$61.9 P/Share
|
|
May 05
2022
|
Emil E Hassan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+8.71%
|
$540,000
$72.94 P/Share
|
|
May 05
2022
|
Richard F Laroche Jr Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.64%
|
$315,000
$63.27 P/Share
|
|
Feb 25
2022
|
Josh A Mc Creary Senior VP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
1,908
+40.07%
|
-
|
|
Feb 25
2022
|
Robert Michael Ussery President & COO |
BUY
Grant, award, or other acquisition
|
Direct |
4,502
+2.89%
|
-
|
|
Feb 25
2022
|
Vicki L Dodson Sr.VP Patient Srvcs |
BUY
Grant, award, or other acquisition
|
Direct |
1,282
+29.2%
|
-
|